Skip to Content

Join the 'Kovaltry' group to help and get support from people like you.

Kovaltry News

FDA Approves Bayer's Kovaltry (Antihemophilic Factor (Recombinant)) for the Treatment of Children and Adults with Hemophilia A

Posted 18 Mar 2016 by

WHIPPANY, N.J., March 17, 2016 /PRNewswire/ – The U.S. Food and Drug Administration has approved Bayer's Kovaltry Antihemophilic Factor (Recombinant), an unmodified, full-length factor VIII compound for the treatment of hemophilia A in children and adults. The approval is based on results from the LEOPOLD (Long-Term Efficacy Open-Label Program in Severe Hemophilia A Disease) clinical trials, ...

Ask a Question

Further Information

Related Condition Support Groups

Hemophilia A

Kovaltry Patient Information at